Is Medtronic Stock a Buy Now? Sales Growth... - Oct 15

The Big Picture

Medtronic raised its full-year outlook after reporting higher fiscal first-quarter profit and sales, but the stock has underperformed the broader market, leaving investors with a nuanced decision. That mix of improving fundamentals and headline structural change, the MiniMed split-off, matters for how you size or time any exposure to $MDT.

The shares returned 1.9% over the past year versus a 17.3% gain for the S&P 500, underscoring the gap between recent operational momentum and market performance.

What's Happening

Recent company disclosures and analyst summaries show revenue momentum and a strategic reshaping of the business. Key data points investors are using to reassess $MDT include the following.

• 1.9%: Medtronic's trailing 12-month return, highlighting relative underperformance versus peers and indices.
• 17.3%: The S&P 500's gain over the same period, a useful benchmark for comparison.
• Raised outlook: Management updated its full-year outlook in September after reporting higher fiscal first-quarter profit and sales, signaling improving near-term fundamentals.
• MiniMed Group split-off: Medtronic plans to spin off MiniMed Group, meaning the company investors buy today will be materially different after the separation.
• 13.19%, 6.39%, 0.06%, 0%: Additional numeric data points are available for valuation analysis and should be factored into any model you use.
• Estimated earnings date: Nov 17, 2026, is listed as an upcoming catalyst that could move the stock as the market digests fresh results.

Each of these points connects to investor relevance: the outlook raise and improved profit and sales are signs of operational recovery, while the split and past relative weakness raise questions about valuation and shareholder returns going forward.

Why It Matters For Your Portfolio

The combination of a raised outlook and a planned spin-off changes how $MDT fits in different portfolios. Growth-oriented investors will watch whether the sales acceleration is sustainable. Value investors may reassess valuation once the MiniMed separation is clearer, and traders will likely focus on near-term catalysts like the estimated Nov 17 earnings date.

Analyst sentiment was not detailed in the source coverage, so market reaction to upcoming results and clarity on the split will be an important barometer for outside views.

Risks To Consider

• Execution risk on the MiniMed split-off, which could create short-term operational distraction and valuation uncertainty as the businesses reprice independently.
• Continued market underperformance, shown by the 1.9% trailing return versus the S&P 500's 17.3%, could persist if sales acceleration falters or investor sentiment remains weak.
• Event-driven volatility around the estimated Nov 17 earnings date, where results or guidance could disappoint even after recent outlook upgrades.

What To Watch Next

Focus on a short list of catalysts and metrics to decide how $MDT should sit in your allocation.

• Estimated Nov 17, 2026 earnings date, which could confirm whether sales and profit trends continue.
• Clarity and timeline for the MiniMed Group split-off, including any guidance on standalone financials or capital allocation plans.
• Sales growth and profit margins in upcoming quarters, to see whether the September outlook raise reflects sustainable trends.
• Valuation inputs and model checks using available figures such as 13.19%, 6.39%, 0.06%, and 0% as part of sensitivity analysis.

The Bottom Line

• Medtronic reported higher fiscal Q1 profit and sales and raised its outlook, indicating improving operating momentum.
• The stock has lagged the S&P 500 over the past year, showing a disconnect between fundamentals and market performance.
• The planned MiniMed split-off changes the investment case, so ownership today may not equate to exposure after the separation.
• Watch the estimated Nov 17 earnings date and updated metrics on sales growth and margins before altering position sizes.
• Use the listed numeric data points in your valuation model and wait for post-split clarity if you need a cleaner comparability profile.

FAQ

Q: Is Medtronic's sales growth strong enough to justify buying now?

A: The company reported higher fiscal Q1 sales and raised its outlook, which indicates improving growth, but investors should wait for follow-up quarters and clarity on the MiniMed split before concluding the trend is sustainable.

Q: How will the MiniMed split affect Medtronic shareholders?

A: The split-off will change the business investors own, introducing execution and valuation uncertainty. Expect several quarters of transition before standalone financial profiles become clear.

Q: What near-term event should investors monitor most closely?

A: The estimated Nov 17, 2026 earnings date is the next major catalyst to watch for confirmation of sales and profit trends and any updated guidance that could move the stock.